The store will not work correctly when cookies are disabled.
Cookie Policy:This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Broad-range cathepsin inhibitor (for all known cathepsins) useful for inflammasome inhibition. Inhibits cathepsins B, L, S, C, V, K and papain in cell-free assays. Inhibits cathepsin X as well.
Suppresses particle-induced NLRP3 activation and IL-1beta secretion more efficiently than Ca074Me (cathepsin B inhibitor), which in contrast suppresses nigericin-induced IL-1beta secretion.
Selectively inhibits particle-induced cell death but not nigericin- or sAdT-induced cell death.
Potent and selective CCR4 antagonist.
Potent, irreversible cysteine protease inhibitor.
Potent cysteine protease cruzain (cruzipain) inhibitor. Active against Trypanosoma cruzi the causative agent of Chagas' disease, a parasitic infection which is a leading cause of heart disease.
Antiparasitic agent with anti-trypanosomal , anti-leishmanial, anti-schistosomiasis, anti-amebiasis (EhCP1 (E. Histolytica cysteine proteinase 1)), anti-anthelmintic (hookworm first-stage larvae) and anti-cryptosporidial activity.
Shown to have antiviral activity by targeting cathepsin-mediated cell entry.
Product References
Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection: J. Engel, et al.; J. Exp. Med. 188, 725 (1998)
In vitro evaluation of the disposition of A novel cysteine protease inhibitor: W. Jacobsen, et al.; Drug Metab. Dispos. 28, 1343 (2000)
Leishmania tropica: cysteine proteases are essential for growth and pathogenicity: H. Mahmoudzadeh-Niknam, et al.; Exp. Parasitol. 106, 158 (2004)
A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi: S.C. Barr, et al.; Antimicrob. Agents Chemother. 49, 5160 (2005)
Use of recombinant Entamoeba histolytica cysteine proteinase 1 to identify a potent inhibitor of amebic invasion in a human colonic model: S.G. Melendez-Lopez, et al.; Eukaryot. Cell 6, 1130 (2007)
Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor: M.H. Abdulla, et al.; PLoS Med. 4, e14 (2007)
Vinyl sulfones as antiparasitic agents and a structural basis for drug design: I.D. Kerr, et al.; J. Biol. Chem. 284, 25697 (2009)
In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi: Y.T. Chen, et al.; PLoS Negl. Trop. Dis. 4, e825 (2010)
Cure of hookworm infection with a cysteine protease inhibitor: J.J. Vermeire, et al.; PLoS Negl. Trop. Dis. 6, e1680 (2012)
Mapping inhibitor binding modes on an active cysteine protease via NMR spectroscopy: G.M. Lee, et al.; Biochem. 51, 10087 (2012)
Active cathepsins B, L, and S in murine and human pancreatitis: V. Lyo, et al.; Am. J. Physiol. Gastrointest. Liver Physiol. 303, G894 (2012)
Internalization of CCR4 and inhibition of chemotaxis by K777, a potent and selective CCR4 antagonist: T. Sato, et al.; Pharmacology 91, 305 (2013)
A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection: M. Ndao, et al.; Antimicrob. Agents Chemother. 57, 6063 (2013)
Reversible cysteine protease inhibitors show promise for a Chagas Disease cure: M. Ndao, et al.; Antimicrob. Agents Chemother. 58, 1167 (2014)
Protease inhibitors targeting coronavirus and filovirus entry: Y. Zhou, et al.; Antiviral Res. 116, 76 (2015)
Multiple cathepsins promote inflammasome-independent, particle-induced cell death during NLRP3-dependent IL-1beta activation: G.M. Orlowski, et al.; J. Leukoc. Biol. 102, 7 (2017)
Download PDF 
Lactacystin AG-CN2-0104